Cancer patient demands rarely lead to unnecessary tests and treatments

May 14, 2014

Despite claims suggesting otherwise, inappropriate cancer patient demands are few and very rarely lead to unnecessary tests and treatments from their health care providers, according to new results from a study that will be presented by researchers in the Abramson Cancer Center (ACC) and the Perelman School of Medicine at the University of Pennsylvania during the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago in early June (Abstract #6530).

The Penn Medicine team, including lead author Keerthi Gogineni, MD, MSHP, an instructor in the division of Hematology-Oncology in the ACC, surveyed 26 oncologists and nurse practitioners immediately after patient encounters at the ACC—2,050 in total—to determine frequency of patient requests or demands for tests and treatment, whether those requests were appropriate, whether they were granted and why.

"The results from this new study help debunk many of the misconceptions people have about patient demands leading to unnecessary tests and treatments as a major source of higher health care costs in the US," said Gogineni. "In this study, inappropriate cancer patient demands were uncommon, and in less than 1 percent of the cases did providers order an inappropriate treatment or test when requested by patients.

"Clinicians felt that the majority of patient directed requests were appropriate. The data suggests that rather than being driven by patients to employ low-value, high cost care, most of the time oncologists and incorporated patients' requests into a suitable plan of action."

Questions about patient demands were raised last year after results from a study presented at ASCO by Penn Medicine researchers revealed that over 80 percent of the general public, 69 percent of patients, and 70 percent of doctors surveyed believed hospitals and doctors conducted unnecessary tests and provided unnecessary treatments, and over 50 percent believed patients requested unnecessary tests or treatments.

Was this happening and could demands be part of the problem? The questions are important ones to explore, particularly in the oncology setting, where drugs and tests can get expensive.

To find out, the team, including Ezekiel J. Emanuel, MD, PhD, chairman of the department of Medical Ethics and Health Policy, broke down the 177 encounters where patients had requests or demands regarding treatment or tests.

The survey revealed that nearly 80 percent of the time the requests or demands from patients were deemed appropriate by the clinician and followed through. The rest were considered inappropriate based on the clinician's judgment and were not ordered. Of the total number of encounters, there were only four instances (0.2 percent) where a clinician ordered an inappropriate test or treatment because of a patient's demand.

The patient base was mostly non-Hispanic white (73 percent) with a mean age of 60. Overall, 42 percent had advanced stage or refractory disease, and 66 percent were undergoing active treatment—49.5 percent had palliative intent. Among the 26 clinicians surveyed, 97 percent were white, 54 percent were female and had a median of 14 years of post-training experience. Too few cases of inappropriate test ordering and treatments precluded the team from making any associations with demographics or disease state to the patient or provider base.

"Rightfully, there is a big push towards more cost-effective care," said Gogineni. "Oncology in particular has been under the lens because of expensive tests and treatments that sometimes have marginal positive effects. So it's important to show the influence of demands and requests, which appear to be very uncommon among cancer patients—and most likely do not drive overutilization of high cost or low-value medical services."

Gogineni will present the team's findings at ASCO on Tuesday, June 3, 2014 in the Health Services Research poster session from 8 a.m. to 11 a.m. in McCormick Place E354b.

Explore further: Most docs believe patients get too many medical tests

Related Stories

Most docs believe patients get too many medical tests

May 7, 2014
(HealthDay)—Most physicians believe that doctors order too many medical tests, yet half admit to doing so themselves in response to a pushy patient, a new survey shows.

Study finds broad support for rationing of some types of cancer care

May 15, 2013
The majority of cancer doctors, patients, and members of the general public support cutting health care costs by refusing to pay for drugs that don't improve survival or quality of life, according to results of a new study ...

Shared decision making improves patient satisfaction during radiation therapy

April 14, 2014
Taking an active role in their radiation treatment decisions leaves cancer patients feeling more satisfied with their care, and may even relieve psychological distress around the experience, researchers from the Perelman ...

Cancer drug shortages hit 83 percent of US oncologists

June 3, 2013
Eighty-three percent of cancer doctors report that they've faced oncology drug shortages, and of those, nearly all say that their patients' treatment has been impacted, according to a study from researchers at the Abramson ...

Patient requests for specific drugs have major impact on prescribing

March 14, 2014
Patient requests for specific medications—including requests for brand-name drugs spurred by direct-to-consumer (DTC) advertising—have a substantial impact on doctors' prescribing decisions, suggests a study in the April ...

Experts issue treatment guidelines for aggressive form of breast cancer

May 5, 2014
(HealthDay)—Two sets of guidelines for treating patients with an aggressive form of breast cancer have been released by the American Society of Clinical Oncology (ASCO).

Recommended for you

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.